ORTHOCLONE OKT3 (Muromonab-CD3) drug information & product resources from MPR including dosage information, educational materials, & patient. Product Overview: Recombinant monoclonal antibody to Human CD3. Muromonab-CD3 (trade name Orthoclone OKT3,) is an immunosuppressant drug given to. decade. The introduction of Orthoclone OKT3 into clinical trials and its subse- quent approval by the Food and Drug Administration in for use as an antire-.


Author: Alf Hilpert
Country: Ethiopia
Language: English
Genre: Education
Published: 28 March 2017
Pages: 629
PDF File Size: 8.37 Mb
ePub File Size: 41.89 Mb
ISBN: 443-4-30127-247-7
Downloads: 31473
Price: Free
Uploader: Alf Hilpert


Most commonly, these are "preferred" on formulary brand drugs. Most commonly, these are "non-preferred" brand drugs. Neurological side effects like aseptic meningitis and encephalopathy have been orthoclone okt3.

Muromonab-CD3 - Wikipedia

Possibly, they are also orthoclone okt3 by the T cell activation. It can also lead to an anaphylactic reaction against the mouse protein, [2] which may be difficult to distinguish from a CRS.

Contraindications[ edit ] Except under special circumstances, the drug is contraindicated for patients with an allergy against mouse proteins, as orthoclone okt3 as patients with uncompensated heart failureuncontrolled arterial hypertension or epilepsy.


orthoclone okt3 It should not be used during pregnancy or lactation. Anaphylactic and anaphylactoid reactions. Should be administered by physician experienced in immunosuppressive therapy and management of solid organ transplant patients.

Discontinue if hypersensitivity is orthoclone okt3 do not resume therapy or re-expose patient.


Have epinephrine and other emergency life-support equipment available. However, check with your doctor or nurse immediately if you have chest pain, rapid or irregular heartbeat, shortness of breath or orthoclone okt3, or swelling of the face or throat after any dose.

Pediatric Muromonab-CD3 (Orthoclone OKT3®) Immunosuppressant

Although not all of these side effects may occur, if they do occur they may need medical attention. Because of the way that muromonab-CD3 acts on the body, there is a chance that it may orthoclone okt3 effects that may not occur until years after the medicine is used.

These delayed effects may include certain types of cancer, such as lymphomas and skin cancers. Discuss these possible effects with your doctor.


Although not all of the following side effects may occur, if they do occur, they may need medical attention.

The overall effect of OKT3 is likely an aggregate effect of interrupted TCR binding, TCR internalization, cytokine-mediated regulatory changes, disrupted trafficking, and cell depletion. OKT3 has proven efficacy as an induction and rescue agent.

Its immunogenicity has orthoclone okt3 its use as a maintenance agent, and the drug is effective only in combination with other immunosuppressive compounds.


Induction Initial trials with OKT3 have shown that this MAb orthoclone okt3 an efficacious induction agent in kidney transplantation, but orthoclone okt3 when combined with otherwise effective maintenance immunosuppression. OKT3 cannot prevent rejection beyond the period of its actual infusion without additional maintenance therapy.

Its usefulness as an induction agent is most pronounced in sensitized patients and patients with delayed graft function, in whom it facilitates the delay of calcineurin inhibitor administration and the resultant nephrotoxicity.